Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Terashima M, Kim YW, Boku N, Chung HC, Chen JS, Ji J, Yeh TS, Chen LT, Ryu MH, Kim JG, Omori T, Rha SY, Kim TY, Ryu KW, Sakuramoto S, Nishida Y, Fukushima N, Yamada T, Bai LY, Hirashima Y, Hagihara S, Nakada T, Sasako M.
Kang YK, et al. Among authors: ji j.
Lancet Gastroenterol Hepatol. 2024 Jun 18:S2468-1253(24)00156-0. doi: 10.1016/S2468-1253(24)00156-0. Online ahead of print.
Lancet Gastroenterol Hepatol. 2024.
PMID: 38906161